$200MM and Counting: What’s Next for the Movement to Invest in Women Entrepreneurs
07/15/2026 - Twenty-two years ago, Golden Seeds set out with a simple idea: women-led companies deserve the same opportunity to build, grow, and access capital as everyone else. I am so proud of what our members, founders, and partners have built over that time and...
Moving Beyond Performative Entrepreneurship
Tucson, AZ 07-15-2026 - If Tucson is to transition from a generalized incubator of ideas into an industrial anchor of the modern economy, the region has to raise its standards. It is time to stop funding activity and start demanding outcomes. I hope some of you are...
iQure Pharma has received a research grant from the The Michael J. Fox Foundation for Parkinson’s Research
06/21/2026 - iQure Pharma, a clinical-stage biotech company developing first-in-class astrocyte-targeted therapies designed to restore glutamate balance in CNS disorders, today announced it has been awarded a research grant from The Michael J. Fox Foundation for...
Delta Development Team Milestone Achievement
06/12/2026 - Delta Development Team, Inc., a multiple-time Desert Angels Portfolio company, announces achievement of a sustained recurring revenue milestone of greater than $1MM per month. This is the result of the efforts of a well-focused and managed team, which has...
iQure Pharma Inc. Chief Scientific Officer recently published
06/07/2026 - Second-Generation of Deuterium-Substituted Glutamate Uptake Enhancers Exhibit Superior Drug-Like Properties in Preclinical Evaluation. This is a key element of the product development work at iQure Pharma. This important publication will be of greatest...
NuvOx Announces Positive Completion of 2nd Cohort in EXTEND-1b Trial
NuvOx Therapeutics (“NuvOx”), a clinical-stage biotechnology company developing oxygen therapeutics for life-threatening hypoxemic conditions, today announced positive preliminary results from the second cohort of its ongoing EXTEND Phase Ib clinical trial of NanO₂™...
Time to Update the Model – The Aging Angel Investment Thesis
A tiny minority of historical applicants that we turn down add us to their investor email list and send us regular updates. It is easy to ask ourselves whether these are missed opportunities, given the high-engagement investor communication skills on display. But when...
CircleIn – Q1 2026 Investors and Advisors Update
Thrilled about our AI Tutor product success (see video), the company largely depends on it becoming a commercial success in this AI era. Learn the Full Story here!